Delivery Order SPE2DB20D3103-SPE2DB25FP7K1
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,847.66 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic medication used to treat autoimmune conditions. This firm fixed-price delivery order, with an ultimate completion date of August 5, 2025, was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine...
- The Defense Logistics Agency awarded a delivery order valued at $1,529.47 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) CF Pen 40 mg/0.4 mL pharmaceutical supply. This contract, awarded on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order valued at $3,214.62 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mls, a injectable medication used to treat autoimmune conditions. The contract, issued on July 30, 2025, is a firm fixed price delivery order with an ultimate completion date of July 31, 2025. The award carries no set-aside designation and represents a competitively awarded transaction. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a $1,132.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic medication used to treat autoimmune inflammatory conditions. The delivery order, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, was issued without a set-aside designation, indicating it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $4,531.80 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL units. This is a firm fixed price delivery order with an ultimate completion date of August 1, 2025, and represents a non-set-aside competitive award. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major pharmaceutical distributor supporting...
- The Defense Logistics Agency awarded a delivery order valued at $5,857.24 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on July 18, 2025, with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product...
- The Defense Logistics Agency awarded a delivery order valued at $5,485.29 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) pen injections, 40 mg/0.4 mL. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 31, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic medication prescribed for autoimmune conditions including...
- The Defense Logistics Agency awarded a $7,022.45 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-competitive delivery order is issued under a firm fixed-price arrangement and represents a single pharmaceutical supply transaction sourced from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. HUMIRA is a widely prescribed biologic immunosuppressant used to...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of HUMIRA (adalimumab) prefilled pens at 40 mg/0.4 mL. This non-competitive, firm fixed-price delivery order is valued at $116,800.12 and is due for completion by August 5, 2025. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $19,774.30 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a ceiling value of $999,999,999.00 through December 2026. The performance location is AmerisourceBergen's...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP7K1Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,135.67 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) pen 40 mg/0.4 mL, a biologic immunosuppressant medication commonly used to treat autoimmune conditions. This firm fixed-price delivery order, awarded on August 5, 2025, with an ultimate completion date of August 6, 2025, represents a non-competitive set-aside award. The place of performance is AmerisourceBergen Drug Corp's corporate office in Conshohocken, Pennsylvania. This order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor vehicle running through December 2026 that provides pharmaceutical and medical supply support to military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company holds a substantial portfolio of competitively awarded delivery orders with DLA covering a diverse range of medications and medical supplies. This specific delivery order for HUMIRA reflects the company's role in ensuring pharmaceutical availability for military medical personnel and beneficiaries through the DLA's comprehensive pharmaceutical prime vendor program.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.1k | 8/5/25 |